



Press release

May 4th, 2021

AlgoDx's NAVOY[®] Sepsis gets CE mark for AI-powered sepsis prediction software

AlgoDx, a clinical stage medical device software company, today announces the obtention of the CE mark for NAVOY[®] Sepsis. This medical device is intended to assist medical staff at Intensive Care Units (ICU) to predict sepsis in adult ICU patients.

- We are proud to announce the CE conformity marking of our product NAVOY[®] Sepsis. In addition to giving AlgoDx authorization to commercialize the product within the EU, the CE mark further opens up opportunities for accelerated registration on other markets, says Maria Sandqvist, QA & Operations Manager.

NAVOY[®] Sepsis is a prediction algorithm based on machine learning that, using only clinical variables routinely collected in Electronic Healthcare Records, predicts the risk of ICU patients developing sepsis in the coming hours.

- By obtaining the CE mark for NAVOY[®] Sepsis, we hope to support the work of intensive care professionals with its comprehensive machine learning-powered sepsis prediction solution, says Andreas Macura, Chief Product Officer. The real benefits of 24/7 bedside monitoring of sepsis risk are the clinical implications of faster diagnosis and monitoring, given that, in sepsis treatment, the time factor is critical, continues Andreas Macura.

About Sepsis and Sepsis Prediction

Sepsis can lead to multiple organ damage and is a potentially life-threatening condition that occurs when the body's response to fight an infection is out of balance. Sepsis affects more than 30 million people worldwide yearly, potentially leading to 6 million deaths. In sepsis treatment, the time factor is critical, where the cornerstones of intervention are early and appropriate antibiotics together with source control and fluid administration. Current detection methods for sepsis are incapable of early prediction. AlgoDx's solution lies in the deployment of a machine learning-based prediction algorithm that, using only parameters that are routinely collected on Electronic Health Records, accurately predicts sepsis in ICU patients.

About AlgoDx

AlgoDx is a clinical stage medical device software company developing a portfolio of novel machine learning algorithms that can predict disease or worsening of disease. Focus areas include sepsis, acute kidney injury, inflammatory bowel disease and hepatitis B.

AlgoDx AB, Bastugatan 12B, Stockholm, algodx.com. Press contact: David Becedas, CEO.
Tel: +46 72 232 83 48. Mail: david.becedas@algodx.com